Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma

Yang, Yang; Li, Guangbing; Lu, Ziwen; Liu, Yong; Kong, Junjie; Li, Jun

doi:10.3389/fonc.2021.726213

Cited by 24 publications

(23 citation statements)

References 116 publications

(136 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AFP and PIVKA‐II are significant in the evaluation of treatment efficacy and prognosis of HCC. Patients with elevated PIVKA‐II are more prone to recurrence and metastasis 11,12 . However, there are few reports on the correlation between serum AFP and PIVKA‐II in the prognosis of HCC patients.…”

Section: Introductionmentioning

confidence: 99%

Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma

Tian

Chen

Zhang

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background The accuracy of alpha‐fetoprotein (AFP) as a diagnostic marker for hepatocellular carcinoma (HCC) is insufficient, and the application of abnormal prothrombin (PIVKA‐II) in HCC is still controversial. Methods Serum AFP and PIVKA‐II levels were analyzed in 145 cases of HCC, 57 of benign liver disease, 55 of cholangiocarcinoma and gallbladder carcinoma, 112 of other gastrointestinal tumors with liver metastasis, and 101 healthy controls. Receiver operating characteristic curve and area under the curve were used to evaluate the diagnostic value of AFP and PIVKA‐II for HCC. The changes in serum AFP and PIVKA‐II levels before and after treatment in 47 HCC patients who underwent surgery and 77 who received interventional treatment were used to evaluate treatment efficacy and prognosis in HCC. Results The concentrations of AFP and PIVKA‐II in the HCC group were significantly higher than those in other groups (p < 0.01). The diagnostic value of PIVKA‐II in HCC was better than that of AFP, and combined detection improved the diagnostic sensitivity and specificity. The levels of AFP and PIVKA‐II after liver cancer surgery were significantly lower than those before surgery. Elevated levels of PIVKA‐II before surgery predicted disease progression, and patients who remained positive for PIVKA‐II after surgery had worse prognosis than those who became negative after surgery. Conclusions Combined detection of AFP and PIVKA‐II is superior to both tests alone. We found that higher serum level of PIVKA‐II indicates more severe HCC, with worse prognosis, while the level of AFP had no correlation with the prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma

Tian

Chen

Zhang

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“… 68 , 292 , 293 Of note, several emerging biomarkers, such as prothrombin induced by vitamin K absence-II (PIVKA-II), featuring a higher sensitivity and specificity than AFP have not yet been widely deployed in preclinical and clinical settings. 294 The limitation of geographic populations and underlying liver disease, and the uncertain biomechanisms to some extent contribute to the existing disappointing situation. Further well-designed, large-scale, and international multicenter prospective clinical studies as well as in-depth mechanistic studies are warranted to validate the clinical power of these biomarkers.…”

Section: Discussionmentioning

confidence: 99%

Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook

Fan¹,

Xue²,

Zheng³

2022

JHC

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) has emerged the culprit of cancer-related mortality worldwide with its dismal prognosis climbing. In recent years, ground-breaking progress has been made in systemic therapy for HCC. Targeted therapy based on specific signaling molecules, including sorafenib, lenvatinib, regorafenib, cabozantinib, and ramucirumab, has been widely used for advanced HCC (aHCC). Immunotherapies such as pembrolizumab and nivolumab greatly improve the survival of aHCC patients. More recently, synergistic combination therapy has boosted first-line (atezolizumab in combination with bevacizumab) and second-line (ipilimumab in combination with nivolumab) therapeutic modalities for aHCC. This review aims to summarize recent updates of systemic therapy relying on the biological mechanisms of HCC, particularly highlighting the approved agents for aHCC. Adjuvant and neoadjuvant therapy, as well as a combination with locoregional therapies (LRTs), are also discussed. Additionally, we describe the promising effect of traditional Chinese medicine (TCM) as systemic therapy on HCC. In this setting, the challenges and future directions of systemic therapy for HCC are also explored.

show abstract

“…PIVKA-II in combination with serum α-fetoprotein (AFP) enhanced the accuracy of surveillance of HCC in high-risk populations. Additionally, PIVKA-II acts as a marker for the assessment of response to treatment in HCC ( Yang et al, 2021 ). Hitomi et al investigated the antitumor effects of vitamin K2 on athymic BALB/c-nu/nu mice.…”

Section: Vitamin K2-7 and Associated Diseasesmentioning

confidence: 99%

Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities

Jadhav¹,

Ajgaonkar²,

Saha³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Vitamin K2-7, also known as menaquinone-7 (MK-7) is a form of vitamin K that has health-beneficial effects in osteoporosis, cardiovascular disease, inflammation, cancer, Alzheimer’s disease, diabetes and peripheral neuropathy. Compared to vitamin K1 (phylloquinone), K2-7 is absorbed more readily and is more bioavailable. Clinical studies have unequivocally demonstrated the utility of vitamin K2-7 supplementation in ameliorating peripheral neuropathy, reducing bone fracture risk and improving cardiovascular health. We examine how undercarboxylated osteocalcin (ucOC) and matrix Gla protein (ucMGP) are converted to carboxylated forms (cOC and cMGP respectively) by K2-7 acting as a cofactor, thus facilitating the deposition of calcium in bones and preventing vascular calcification. K2-7 is beneficial in managing bone loss because it upregulates osteoprotegerin which is a decoy receptor for RANK ligand (RANKL) thus inhibiting bone resorption. We also review the evidence for the health-beneficial outcomes of K2-7 in diabetes, peripheral neuropathy and Alzheimer’s disease. In addition, we discuss the K2-7-mediated suppression of growth in cancer cells via cell-cycle arrest, autophagy and apoptosis. The mechanistic basis for the disease-modulating effects of K2-7 is mediated through various signal transduction pathways such as PI3K/AKT, MAP Kinase, JAK/STAT, NF-κB, etc. Interestingly, K2-7 is also responsible for suppression of proinflammatory mediators such as IL-1α, IL-1β and TNF-α. We elucidate various genes modulated by K2-7 as well as the clinical pharmacometrics of vitamin K2-7 including K2-7-mediated pharmacokinetics/pharmacodynamics (PK/PD). Further, we discuss the current status of clinical trials on K2-7 that shed light on dosing strategies for maximum health benefits. Taken together, this is a synthetic review that delineates the health-beneficial effects of K2-7 in a clinical setting, highlights the molecular basis for these effects, elucidates the clinical pharmacokinetics of K2-7, and underscores the need for K2-7 supplementation in the global diet.

show abstract

Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma

Cited by 24 publications

References 116 publications

Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma

Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma

Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook

Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities

Contact Info

Product

Resources

About